EGFR and non-small cell lung carcinoma: Our team is currently utilizing the Cre-LoxP system to generate a transgenic EGFR-mutant NSCLC mouse model, which will be used to assess ZEB2 inhibition in the immunocompetent mouse model and to explore its potential synergistic effect with immunotherapy.